The Food and Drug Administration on Thursday gave market clearance to Cardiac Insight's wearable electrocardiogram sensor, Cardea Solo.
Cardea Solo is a small, lightweight, disposable sensor patients can wear under their clothes for up to one week. The device collects and analyzes ECG data to help clinicians quickly diagnose arrthymias or heart issues.
Cardiac Insights expects the device to decrease the average time for cardiac diagnosis and treatment.
More articles on supply chain:
Global pharmerging market to reach $1.4B by 2025
Price hikes likely added $8.7B to pharma's net income for 2016, report finds
ASCO: Strategies to control drug costs hinder cancer patient care